REGEN-COV Antibody Cocktail Reduced Hospitalisation/Death By
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
In October, former President Donald Trump received Regeneron’s drug after he was infected with Covid-19 and later credited the medicine with his speedy recovery. The initial authorizations in November were based on preliminary data from smaller earlier-stage studies. In recent weeks, the companies have issued findings from much larger studies that confirm the benefits seen in the earlier analyses.

The latest data comes from a Phase 3 study that compared two doses of Regeneron’s drug, named REGEN-COV, with placebos in more than 4,000 Covid-19 patients with at least one risk factor such as obesity or cardiovascular disease. The lower dose reduced the risk of hospitalization or death in study subjects by 70%, Regeneron said.

In the higher dose group, 1.3% of patients taking the drug were hospitalized or died, compared with 4.6% of those who received placebos, a 71% reduction of risk. There was one patient death in each of the Regeneron drug study groups, and five deaths across both of the placebo groups. “We are committed to working with the government, healthcare providers and others to support rapid and widespread adoption of REGEN-COV in appropriate patients,” said George D. Yancopoulos, Regeneron president and chief scientific officer.

Regeneron’s data suggest the drug’s effectiveness is similar to Eli Lilly’s drug cocktail, which combines a new monoclonal antibody, named etesevimab, to one called bamlanivimab that was authorized last year. The FDA authorized the cocktail in February based on trial data showing it reduced hospitalizations or death by 70%.

Regeneron also said that the FDA recently updated a fact sheet on the drug to show that in laboratory tests it is no less effective against new coronavirus variants that were first identified in the U.K., South Africa and elsewhere.

Source:
https://investor.regeneron.com/news-releases/news-release-details/phase-3-trial-shows-regen-covtm-casirivimab-imdevimab-antibody
Dr. N●●●i S●●●●●●a and 2 other likes this
Like
Comment
Share